AL-15469A for the Treatment of Bacterial Conjunctivitis
1 other identifier
interventional
600
1 country
1
Brief Summary
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2005
CompletedFirst Submitted
Initial submission to the registry
May 30, 2006
CompletedFirst Posted
Study publicly available on registry
May 31, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2007
CompletedSeptember 29, 2009
September 1, 2009
1.5 years
May 30, 2006
September 25, 2009
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical cure and microbiological success
Secondary Outcomes (1)
Individual signs and symptoms of bacterial conjunctivitis at each visit
Interventions
Eligibility Criteria
You may qualify if:
- Signs \& Symptoms of conjunctivitis
You may not qualify if:
- Under 1 mo. age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Alcon Researchlead
Study Sites (1)
US
Fort Worth, Texas, 76134, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Stella Robertson, Ph.D.
Study Director
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 30, 2006
First Posted
May 31, 2006
Study Start
November 1, 2005
Primary Completion
May 1, 2007
Last Updated
September 29, 2009
Record last verified: 2009-09